Webinar: 'organ on a chip: Bridging biology and technology in efficacy and ADME testing’

Online • 09 Mar 2022

Watch the recording of the webinar 'Organ on a chip'.
During this 1 hour webinar, we share the results of TNO's research programme on Organ on a chip and announce future initiatives that are open for partnering.

About TNO's research prograMme

With the need for better predictive models for pre-clinical testing and the development of more advanced technologies to keep (human) cells alive, organ-on-a-chip technologies have become increasingly important in the drug development process.

TNO has a long  track record in understanding the biology in disease development and drug PK and metabolism. In the last five years TNO invested in connecting those two with its expertise in Organ on a chip technology to find its application in better predictive, non-animal alternatives for drug efficacy and ADME testing.

This has led to the development of a liver on a chip model to test drug efficacy (in NASH/fibrosis) as well as an InTESTine on a chip model to study ADME and the effects of microbiome on drug metabolism.


Introduction TNO and the Organ on a chip research programme:

Robert Ostendorf, Senior Business Development Manager, TNO

InTESTine on a chip: in vitro ADME model to study the effect of microbiome too

Evita van de Steeg, Senior Scientist, TNO

Intact ex vivo intestinal tissue is used in our models of the gut wall, InTESTine™ and the Intestinal Explant Barrier Chip (IEBC). The wells-plate or microfluidic chip setup allows monitoring many processes that take part in the gut wall, such as transport, barrier function, metabolic activity, hormone secretion, and the inflammatory response. Special attention will be paid to the possibility to study the impact of your compound on the gut tissue as well as on the interaction of the gut wall with the microbiome.

Liver on a chip – an in vitro efficacy model for NASH-fibrosis

Geurt Stokman, Senior Scientist, TNO

The Liver on a chip model is a co-culture model of primary human hepatocytes, stellate cells and Kupffer cells in which NASH fibrosis is being diet-induced and new compounds can be tested on their efficacy in NASH fibrosis. During the webinar our experts give examples of tested interventions as well as an overview of typical read-outs for these types of cultures that are relevant in your preclinical data package. Furthermore, we elaborate on future initiatives using organoids or stem cells as a source for the different cells.

Co-innovation options and wrap up

Robert Ostendorf, Senior Business Development Manager, TNO

Next to the established models, we also give an overview of the different initiatives that TNO is involved in and we will share novel ideas to collaborate on.

  1. Host microbiome interactions: an aerobic-anaerobic interface is to facilitate the direct interaction of the anaerobic gut microbiome with intestinal tissue in the IEBC platform.
  2. Combining the liver and gut on a chip model for better predictive DMPK.

Join the webinar

March 9, from 15.00 - 16.00 hours (CET)

Register here
Our work

Preclinical NASH models

Nonalcoholic steatohepatitis (NASH) is one of the most prevalent chronic liver diseases. The number of patients suffering from NASH is increasing dramatically and is associated with metabolic syndrome,... Read more
Our work

Preclinical predictive models improve drug development pathway

In preclinical settings, effective predictive tools and models can be used to improve the development pathway for new drugs. One potential benefit is reduced drug loss at a later stage of development.... Read more